Mark A Verdicia

Title: Mark A Verdicia: Innovator in Farnesoid X Receptor Research

Introduction

Mark A Verdicia is a notable inventor based in New York, NY (US). He has made significant contributions to the field of biological studies, particularly in the area of farnesoid X receptor (FXR) research. With a total of two patents to his name, Verdicia's work has implications for understanding ligand binding and its applications in drug discovery.

Latest Patents

Mark A Verdicia's latest patents focus on the structure of the farnesoid X receptor ligand binding domain and methods of use therefor. The first patent provides compositions comprising the ligand binding domain (LBD) of FXR in crystalline form. In alternative embodiments, the LBD of FXR is complexed with a ligand. The patent includes high-resolution structures of FXR complexed with a novel high-affinity agonist, fexaramine. This discovery offers the first three-dimensional view of the structural basis for FXR ligand binding. Additionally, the invention provides a computer for producing a time-dimensional representation of FXR or a complex thereof, as well as methods for predicting molecules capable of binding to FXR.

Career Highlights

Mark A Verdicia is affiliated with the Salk Institute for Biological Studies, where he conducts his research. His work has been instrumental in advancing the understanding of FXR and its potential therapeutic applications.

Collaborations

Some of his notable coworkers include Michael Downes and Joseph Noel, who have collaborated with Verdicia on various research projects.

Conclusion

Mark A Verdicia's innovative work in the field of farnesoid X receptor research has led to significant advancements in understanding ligand binding and its applications. His contributions continue to influence the scientific community and pave the way for future discoveries.